Fusion Molecule Detection for FGFR3-TACC3 Cancer Rearrangements
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The need exists for identifying novel genetic lesions associated with cancer, such as complex chromosome structural aberrations, to develop effective compositions and methods for evaluating and treating cancer patients.
Innovation Solution
The discovery of novel rearrangement events leading to fusion molecules, including fragments of genes like FGFR3 and TACC3, which are expressed in cancer tissues and are associated with neoplastic growth, enabling methods for identifying, assessing, and treating cancer through the use of fusion molecules, nucleic acid constructs, host cells, purified polypeptides, and detection reagents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to identify genetic lesions in cancer, then existing diagnostic approaches can be applied, but novel fusion molecules and rearrangement events remain undetected
Solution Approach 1:
The patent segments the detection approach by identifying specific fusion molecules (e.g., FGFR3-TACC3) and rearrangement events as distinct targets. This segmentation allows for specialized detection methods tailored to each fusion type, improving detection precision while maintaining versatility through comprehensive coverage of multiple fusion variants
Solution Approach 2:
The patent introduces fusion-specific detection reagents and intermediary molecules that bridge the gap between conventional diagnostic methods and novel fusion detection. These intermediaries enable existing diagnostic platforms to detect previously undetectable fusion events, enhancing both precision and adaptability
2Adaptability or versatility
If comprehensive screening for all genetic lesions is performed, then all cancer-associated mutations can be detected, but the complexity and cost of testing increases
Solution Approach 1:
The patent develops universal detection platforms that can identify multiple fusion molecules and rearrangement events simultaneously. This multi-functionality allows a single testing system to screen for diverse genetic lesions without proportionally increasing complexity, as the platform is designed to handle various fusion types through standardized procedures
Solution Approach 2:
The patent implements a tiered screening approach where high-risk fusion molecules (such as FGFR3-TACC3 in bladder cancer) are detected with higher priority and specificity. This partial action strategy focuses resources on the most clinically relevant fusions first, providing comprehensive coverage where needed while reducing complexity for lower-priority detections
Data Source
AI summary
Novel fusion molecules and uses are disclosed.